|
English
|
正體中文
|
简体中文
|
2823024
|
|
???header.visitor??? :
30210178
???header.onlineuser??? :
898
???header.sponsordeclaration???
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"hitre e"???jsp.browse.items-by-author.description???
Showing items 1-2 of 2 (1 Page(s) Totally) 1 View [10|25|50] records per page
臺大學術典藏 |
2022-09-15T01:08:47Z |
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Brose M.S.; Robinson B.; Sherman S.I.; Krajewska J.; Chia-Chi Lin; Vaisman F.; Hoff A.O.; Hitre E.; Bowles D.W.; Hernando J.; Faoro L.; Banerjee K.; Oliver J.W.; Keam B.; Capdevila J. |
國家衛生研究院 |
2019-10 |
A randomized controlled, open label, adaptive phase III Trial to evaluate safety and efficacy of endoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FO
|
Chen, LT;Hitre, E;Lee, WJ;Bai, LY;Papai, Z;Kang, SY;Dvorkin, M;Choi, HJ;Oh, SC;Artru, P;Bachet, JB |
Showing items 1-2 of 2 (1 Page(s) Totally) 1 View [10|25|50] records per page
|